174 related articles for article (PubMed ID: 35486213)
1. The miR-183/96/182 cluster is upregulated in glioblastoma carrying EGFR amplification.
Schneider B; William D; Lamp N; Zimpfer A; Henker C; Classen CF; Erbersdobler A
Mol Cell Biochem; 2022 Sep; 477(9):2297-2307. PubMed ID: 35486213
[TBL] [Abstract][Full Text] [Related]
2. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
3. miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma.
Rao SA; Arimappamagan A; Pandey P; Santosh V; Hegde AS; Chandramouli BA; Somasundaram K
PLoS One; 2013; 8(5):e63164. PubMed ID: 23690991
[TBL] [Abstract][Full Text] [Related]
4. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
[TBL] [Abstract][Full Text] [Related]
6. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
[TBL] [Abstract][Full Text] [Related]
7. The Status of
Muñoz-Hidalgo L; San-Miguel T; Megías J; Serna E; Calabuig-Fariñas S; Monleón D; Gil-Benso R; Cerdá-Nicolás M; López-Ginés C
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396457
[TBL] [Abstract][Full Text] [Related]
8. The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway.
Gheidari F; Arefian E; Saadatpour F; Kabiri M; Seyedjafari E; Teimoori-Toolabi L; Soleimani M
Mol Biol Rep; 2022 Dec; 49(12):11855-11866. PubMed ID: 36219319
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
Lo HW
Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
[TBL] [Abstract][Full Text] [Related]
10. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.
Guo Y; He X; Zhang M; Qu Y; Gu C; Ren M; Wang H; Ning W; Li J; Yu C; Zhang H
J Neurooncol; 2020 Apr; 147(2):327-337. PubMed ID: 32170633
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs involved in the EGFR pathway in glioblastoma.
Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
[TBL] [Abstract][Full Text] [Related]
13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab.
Zhang KL; Zhou X; Han L; Chen LY; Chen LC; Shi ZD; Yang M; Ren Y; Yang JX; Frank TS; Zhang CB; Zhang JX; Pu PY; Zhang JN; Jiang T; Wagner EJ; Li M; Kang CS
Mol Cancer; 2014 Mar; 13():63. PubMed ID: 24650032
[TBL] [Abstract][Full Text] [Related]
15. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
17. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of PDGFRB and EGFR in microvascular proliferation in glioblastoma.
Xu G; Li JY
Tumour Biol; 2016 Aug; 37(8):10577-86. PubMed ID: 26857280
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]